NCT00113802View on ClinicalTrials.gov

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Waldenstrom Macroglobulinemia
Interventions
DRUG

Epratuzumab (hLL2- anti-CD22 humanized antibody)

Trial Locations (2)

10021

Weill Medical College of Cornell/ New York Presbyterian Hospital, New York

10032

Columbia University College of Physicans & Surgeons, New York

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00113802 - Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter